Up to half of all patients with metastatic HER2+ breast cancer will eventually acquire brain metastases, which are associated with reduced overall survival and decreased quality of life. This comprehensive review examines current recommendations in 1st, 2nd, and later line therapies, discusses the status of novel agents, and provides recommendations to standardize care.